Published in N Engl J Med on December 14, 2000
A Phase I Extension Trial of Repeated Infusions of ISF35 | NCT00783588
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | NCT00779883
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
DNA interstrand crosslink repair and cancer. Nat Rev Cancer (2011) 4.29
Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005. J Clin Oncol (2009) 2.52
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood (2011) 2.34
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol (2011) 2.26
Update on therapy of chronic lymphocytic leukemia. J Clin Oncol (2011) 2.19
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood (2005) 2.06
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood (2006) 1.92
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood (2005) 1.89
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol (2010) 1.77
How I treat CLL up front. Blood (2009) 1.71
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood (2013) 1.59
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.57
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood (2015) 1.56
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma (2012) 1.49
Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics (2010) 1.37
Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia (2009) 1.30
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol (2012) 1.27
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol (2011) 1.26
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol (2009) 1.24
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood (2011) 1.24
Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica (2009) 1.21
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer (2008) 1.18
Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol (2010) 1.16
When and how to treat chronic lymphocytic leukemia. N Engl J Med (2000) 1.12
Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Ther Clin Risk Manag (2009) 1.12
Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res (2009) 1.10
Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer (2013) 1.07
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia (2013) 1.05
Oblimersen for the treatment of patients with chronic lymphocytic leukemia. Ther Clin Risk Manag (2007) 1.05
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood (2008) 1.04
Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies. Cancer Manag Res (2013) 1.01
Refractory chronic lymphocytic leukemia--new therapeutic strategies. Oncotarget (2010) 1.00
ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC. BMC Cancer (2009) 0.99
DiseaseConnect: a comprehensive web server for mechanism-based disease-disease connections. Nucleic Acids Res (2014) 0.99
Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica (2012) 0.99
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs (2011) 0.98
Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol (2012) 0.98
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res (2009) 0.98
Covalent and noncovalent intermediates of an NAD utilizing enzyme, human CD38. Chem Biol (2008) 0.98
New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia. ISRN Oncol (2013) 0.96
Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant (2009) 0.96
The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias. BMC Med Res Methodol (2008) 0.96
Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther (2013) 0.96
Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer (2011) 0.95
MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget (2012) 0.95
Antibody therapy for chronic lymphocytic leukemia. Semin Hematol (2008) 0.95
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol (2009) 0.95
Chronic lymphocytic leukemia: planning for an aging population. Expert Rev Anticancer Ther (2010) 0.93
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood (2015) 0.93
Ocular toxicity of fludarabine: a purine analog. Expert Rev Ophthalmol (2008) 0.92
Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol (2007) 0.91
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood (2015) 0.89
Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. Blood (2014) 0.88
Role of rituximab in first-line treatment of chronic lymphocytic leukemia. Ther Clin Risk Manag (2010) 0.88
Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia. Blood Rev (2010) 0.87
Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block. Clin Cancer Res (2009) 0.87
Therapeutic antibodies against cancer. Hematol Oncol Clin North Am (2012) 0.87
A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia (2009) 0.87
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clin Cancer Res (2013) 0.86
Management of chronic lymphocytic leukemia. Haematologica (2014) 0.85
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood (2014) 0.84
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer (2010) 0.83
Re-directing an alkylating agent to mitochondria alters drug target and cell death mechanism. PLoS One (2013) 0.83
Therapy related acute myeloid leukemia with t(10:16): a rare entity. Hematol Rep (2011) 0.83
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. Invest New Drugs (2007) 0.83
Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism. PLoS One (2014) 0.83
Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother (2012) 0.82
The role of transporters in the toxicity of nucleoside and nucleotide analogs. Expert Opin Drug Metab Toxicol (2012) 0.82
Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues. Bioorg Med Chem (2012) 0.81
Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs. PLoS One (2013) 0.81
DNA crosslinking damage and cancer - a tale of friend and foe. Transl Cancer Res (2013) 0.81
Infectious complications in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis (2012) 0.80
Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. Haematologica (2011) 0.80
Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. Br J Cancer (2011) 0.80
The spectrum of use of rituximab in chronic lymphocytic leukemia. Onco Targets Ther (2010) 0.80
Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents. Oncotarget (2016) 0.79
Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience. Mediterr J Hematol Infect Dis (2013) 0.78
Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia. Blood Cancer J (2015) 0.78
Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol (2008) 0.78
Repurposing FDA-approved drugs for anti-aging therapies. Biogerontology (2016) 0.77
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. Onco Targets Ther (2010) 0.77
Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis. Curr Oncol (2015) 0.77
Rituximab for the treatment of patients with chronic lymphocytic leukemia. Cancer Manag Res (2010) 0.77
BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia. Mediterr J Hematol Infect Dis (2016) 0.77
Personalized medicine in CLL: current status and future perspectives. Cancer Lett (2013) 0.76
Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy. Leukemia (2015) 0.76
Choosing first-line therapy for chronic lymphocytic leukemia. Expert Rev Anticancer Ther (2011) 0.76
Monoclonal antibodies specific for oncofetal antigen--immature laminin receptor protein: Effects on tumor growth and spread in two murine models. Cancer Biol Ther (2015) 0.76
Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. J Clin Oncol (2017) 0.75
The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies. J Blood Med (2010) 0.75
Role of bendamustine in the treatment of chronic lymphocytic leukemia. Onco Targets Ther (2009) 0.75
Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia. Adv Hematol (2010) 0.75
The biology behind PI3K inhibition in chronic lymphocytic leukaemia. Ther Adv Hematol (2015) 0.75
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 11.57
Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization. A randomized, controlled trial. Ann Intern Med (1998) 7.26
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 6.27
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98
Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A (1997) 5.61
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med (1994) 5.03
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1997) 4.79
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65
Religiosity and remission of depression in medically ill older patients. Am J Psychiatry (1998) 4.11
Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood (1998) 4.07
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res (2001) 3.66
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol (2001) 3.23
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 3.19
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med (1993) 3.18
Glucose metabolism in Neisseria gonorrhoeae. J Bacteriol (1974) 3.01
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
The origin of the chemiluminescence of phagocytosing granulocytes. J Clin Invest (1976) 2.92
The Cook-Medley hostility scale: item content and ability to predict survival. Psychosom Med (1989) 2.90
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol (1986) 2.64
How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J Mol Biol (2000) 2.62
Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med (1989) 2.61
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res (1998) 2.56
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 2.53
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood (2001) 2.52
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol (1998) 2.51
Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med (1995) 2.33
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res (1998) 2.33
A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood (1990) 2.32
Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood (1996) 2.30
Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol (1988) 2.24
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol (2007) 2.17
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11
Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure (2000) 2.10
Studies of the human c-myb gene and its product in human acute leukemias. Science (1986) 2.10
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood (1990) 2.09
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol (1988) 2.06
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res (1996) 1.99
Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemias with a del(5q). Blood (1989) 1.98
The availability of statistics relating to deafness in the United Kingdom. Br J Audiol (1978) 1.98
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood (1993) 1.94
Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders. Science (1986) 1.91
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 1.90
Lipomas of the pancreas. AJR Am J Roentgenol (1998) 1.87
Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med (1983) 1.86
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood (1999) 1.85
Role of cloned carotenoid genes expressed in Escherichia coli in protecting against inactivation by near-UV light and specific phototoxic molecules. J Bacteriol (1988) 1.84
Deletions of interferon genes in acute lymphoblastic leukemia. N Engl J Med (1990) 1.82
Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood (1985) 1.81
Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood (1997) 1.80
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood (1995) 1.79
Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood (1996) 1.77
Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med (1984) 1.76
Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol (1988) 1.72
Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med (1994) 1.71
Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci (1993) 1.70
Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet (1995) 1.69
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood (1997) 1.64
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol (1996) 1.64
Hostility during late adolescence predicts coronary risk factors at mid-life. Am J Epidemiol (1992) 1.64
Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol (2001) 1.63
Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood (1991) 1.63
Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood (1991) 1.61
Prophylactic platelet transfusion. Transfusion (1992) 1.61
Protein kinase C-theta phosphorylation of moesin in the actin-binding sequence. J Biol Chem (1998) 1.60
Retinoids in cancer therapy. J Clin Oncol (1992) 1.59
Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Am J Psychiatry (1997) 1.59
Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med (1997) 1.59
Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. Int J Radiat Oncol Biol Phys (1993) 1.57
Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood (1994) 1.57
Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A (1993) 1.56
Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med (1993) 1.55
Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol (1989) 1.54
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia (2010) 1.54
Coronary artery stretch versus deep injury in the development of in-stent neointima. Heart (2002) 1.54
C-terminal threonine phosphorylation activates ERM proteins to link the cell's cortical lipid bilayer to the cytoskeleton. Biochem Biophys Res Commun (1998) 1.50